Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Federal Realty Investment Trust's fourth-quarter revenue falls short of market expectations due to reduced leasing demand, increased borrowing costs, and ...